Peptides in Panama 2026: what they are, what the law says, what evidence shows

What a peptide is and why the distinction matters

In Panama, the word "peptide" is now used for products that share nothing but their chemistry: short chains of amino acids. Some are among the best-studied drugs of the decade, such as semaglutide and tirzepatide; others, such as BPC-157, circulate as unapproved research substances. A physician needs to separate those two groups before discussing evidence or law. For the general science picture see The peptide universe: a guide for physicians in Panama.

What the DNFD regulates: Law 419 and Executive Decree 27

Medicines in Panama are regulated by the National Directorate of Pharmacy and Drugs (Dirección Nacional de Farmacia y Drogas, DNFD), part of the Ministry of Health (MINSA). Law 419 of 2024 governs medicines and other human health products, and Executive Decree 27 of May 2024, published in Gaceta Oficial 30028-C, implements it¹². Under article 156 of the law, "marketing a product without sanitary registration, except for the authorized exceptions" is a very serious offense, and the fine for those offenses runs from B/.15,001 to B/.25,000, without prejudice to civil or criminal action¹. The decree caps personal import at six months of treatment with a prescription and does not allow raw material by courier².

The articles that most affect the clinic are broken down in Prescribing, importing, administering: a physician's legal map in Panama. Rules for remote prescribing are in Telemedicine in Panama: what a physician may prescribe remotely. This article is not legal advice.

Approved peptides: semaglutide and tirzepatide

On October 23, 2026, the DNFD published a safety note and, drawing on its sanitary registration database, listed nine semaglutide products registered in Panama: Ozempic, Wegovy and Rybelsus, all from Novo Nordisk³. We could not verify tirzepatide's status: the note covers only semaglutide and MINSA's public search tool did not respond³. Details are in GLP-1 drugs in Panama: registrations, prices and CSS, and the epidemiological context in Obesity and diabetes in Panama: the numbers and GLP-1 drugs.

The evidence behind these drugs comes from large trials. In STEP 1, weekly semaglutide was associated with a mean weight reduction of 14.9% at 68 weeks vs 2.4% with placebo¹⁰; in SURMOUNT-1, tirzepatide produced reductions of 15% to 20.9% at 72 weeks depending on dose, vs 3.1% with placebo¹¹. The local controversy is not about the drug but about its use and origin: see Semaglutide for weight loss: Panama's clash. The Pan American Health Organization (PAHO) asked in March 2026 for stronger pharmacovigilance and for limiting these medicines to approved indications⁹.

Counterfeits: the risk of untraceable product

In 2026 the DNFD published alert 018-DNFD-2026 (June 15) on Mounjaro KwikPen 15 mg, lot D719674C, and in late August MINSA warned of another counterfeit lot that "is not registered in Panama"⁴⁵. The World Health Organization (WHO) warns that substandard and falsified medical products are often sold online or in informal markets⁸, and a meta-analysis estimated that 13.6% of essential-medicine samples tested in low- and middle-income countries were of poor quality¹⁶. Full coverage is in Fake Ozempic and Mounjaro: what Panama's MINSA flagged. How to read a certificate of analysis, the HPLC method and the lot number is explained in How to verify a peptide in Panama: COA, HPLC and lot.

Unapproved research peptides: the case of BPC-157

USADA sums up BPC-157's situation: it is not approved for human clinical use by the FDA or any other health authority in the world, and no human clinical trials establish efficacy⁷. The FDA, assessing its possible use in compounding, cited a possible immunogenicity risk and said it has identified no, or only limited, safety information⁶. A 2025 systematic review found 36 studies, only one in humans (12 participants), with level IV and V evidence and no clinical safety data¹². A 2026 review identified three human studies with 30 participants and concluded it should not be used clinically outside approved, regulated trials¹³. The World Anti-Doping Agency places it under section S0 of its prohibited list¹⁷; the athlete angle is in Doping and peptides in Panama sport.

For the market in unregistered regenerative products, the best-documented Panamanian parallel is stem cells: in August 2026 MINSA inspected two establishments and opened administrative files¹⁵, and researchers from the National Research Bioethics Committee called for enforcement¹⁴. See Stem cells in Panama: medical tourism without evidence and Medical tourism in Panama: the numbers and the regenerative push. The comparison between registration regimes is discussed in Sanitary registration: the question asked of peptides but not of exosomes.

Aesthetics and longevity: where they overlap

Peptides also appear in aesthetic medicine and longevity clinics. Who may inject and what cases occurred is in Who may inject fillers and toxins in Panama: the law and the cases; the history of IV drips and mycobacteria in Law 491, IV drips and mycobacteria; and what the evidence does and does not support in this sector in Longevity clinics in Panama: what the evidence says.

What to read next

• Legal framework: the physician's legal map and telemedicine.
• GLP-1: registrations, prices and CSS, obesity and diabetes figures and counterfeits.
• Quality: how to verify a peptide: COA, HPLC and lot.
• Sport: doping and peptides.
• Regenerative and aesthetic medicine: stem cells, medical tourism, longevity.